Peri-Operative Therapy in Bladder Cancer, Parts 1-4

Brian Rini, MD, begins the conference with introductions and a warm welcome. Tom Powles, MBBS, MRCP, MD, then begins the first bladder cancer panel session including Andrea Apolo, MD; Petros Grivas, MD, PhD; Shilpa Gupta, MD; and Kala Sridhar, MD by discussing the addition of durvalumab to SOC in MIBC and its implications prompting practice change as well as other trials in the periop UC space.

Dr. Powles continues to moderate the panel of Drs. Apolo, Grivas, Gupta, and Sridhar as they move into their discussion of combination therapy, the TAR-200 pretzel device, and other bladder-sparing approaches in MIBC.

Tom Powles, MBBS, MRCP, MD, continues the panel session with Andrea Apolo, MD; Petros Grivas, MD, PhD; Shilpa Gupta, MD; and Kala Sridhar, MD, on ctDNA analysis post NIAGARA in MIBC.

Drs. Powles, Apolo, Grivas, Gupta, and Sridhar wrap up the first panel session in bladder cancer by discussing what they each anticipate individually for the future of treatment post the NIAGARA trial.